Cited by 263Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

Kim, Sehee, Moon, Minho, Park, Seungjoon·2009·Journal of Endocrinology

DOI 10.1677/joe-09-0132

Open this paper in CoChat — free account

Abstract

Exendin-4 is a naturally occurring more potent and stable analog of glucagon-like peptide-1 (GLP-1) that selectively binds at the GLP-1 receptor. It has been recently demonstrated that GLP-1 receptor stimulation preserves dopaminergic neurons in cellular and rodent models of Parkinson's disease (PD). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes nigrostriatal dopaminergic neurotoxicity in rodents; previous studies suggest that activated microglia actively participate in the pathogenesis of PD neurodegeneration. However, the role of microglia in the neuroprotective properties of exendin-4 is still unknown. Here, we show that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta (SNpc) neurons and the striatal dopaminergic fibers. Exendin-4 prevents MPTP-induced microglial activation in the SNpc and striatum, and the expression of matrix metalloproteinase-3. In addition, exendin-4 also suppressed MPTP-induced expression of pro-inflammatory molecules and tumor necrosis factor α and interleukin-1β. Our data indicate that exendin-4 may act as a survival factor for dopaminergic neurons by functioning as a microglia-deactivating factor and suggest that exendin-4 may be a valuable therapeutic agent for neurodegenerative diseases such as PD.

Integrity signals

Registry

Crossref · 10.1677/joe-09-0132

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (1909) · JAMA · doi:10.1001/jama.1909.02550020033007 · Cited by 7,889
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 4×
“Microglia-derived NO-mediated nitrate stress plays a pivotal role in the pathogenesis of PD, which is supported by the demonstration that MPTP-induced SNpc dopaminergic neuron loss and the production of ventral midbrain nitrotyrosine are attenuated in mice lacking the iNOS gene (Liberatore et al. 1999).”
Influential
Cytotoxicity of microglia
Banati, R. B., Gehrmann, J., Schubert, P., & Kreutzberg, G. W. (1993) · Glia · doi:10.1002/glia.440070117 · Cited by 1,032
MICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASES
González-Scarano, F., & Baltuch, G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.219 · Cited by 984
Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP.
D'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892

Show all 55 references

Sorted by citations

Items 201–263 of 263

Fraternine, a Novel Wasp Peptide, Protects against Motor Impairments in 6-OHDA Model of Parkinsonism
Mayer, A. B., de Oliveira, D. G. R., Amaral, H. D. O., Campos, G. A. A., Gonçalves, J. C., de Souza, A. C. B., Lima, M. R., Silva, L. P., & Mortari, M. R. (2020) · Toxins · doi:10.3390/toxins12090550 · Cited by 14
What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson’s Disease?
Xue, J., Tao, K., Wang, W., & Wang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031641 · Cited by 19
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Ribarič, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084358 · Cited by 15
Recent Advances in Drug Repurposing for Parkinson’s Disease
Chen, X., Gumina, G., & Virga, K. G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180719144850 · Cited by 13
The protective role of GLP-1 in neuro-ophthalmology
Sheth, S., Patel, A., Foreman, M. A., Mumtaz, M., Reddy, A., Sharaf, R., Sheth, S., & Lucke-Wold, B. P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00015 · Cited by 12
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 16
Therapeutic potential of spinal GLP-1 receptor signaling
Zhang, D., & Lv, G. (2018) · Peptides · doi:10.1016/j.peptides.2018.01.003 · Cited by 13
Exendin-4 Inhibits HMGB1-Induced Inflammatory Responses in HUVECs and in Murine Polymicrobial Sepsis
Lee, W., Ku, S., Park, E. J., Na, D. H., Kim, K., & Bae, J. (2014) · Inflammation · doi:10.1007/s10753-014-9919-9 · Cited by 12
Peptide discovery across the spectrum of neuroinflammation; microglia and astrocyte phenotypical targeting, mediation, and mechanistic understanding
Benita, B. A., & Koss, K. M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1443985 · Cited by 12
Glycolytic metabolism supports microglia training during age-related neurodegeneration
Camacho‐Morales, A. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00363-2 · Cited by 11
What Is the Role of Glucagon-Like Peptide 1 Signaling in the Nervous System and Its Potential Neuroprotective Effects?
Turcano, P., Savica, R., & Benarroch, E. E. (2024) · Neurology · doi:10.1212/wnl.0000000000209781 · Cited by 11
Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D 3 Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra
Harkavyi, A., Rampersaud, N., & Whitton, P. S. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/407152 · Cited by 10
Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinson’s Disease
Tang, Y., Yang, K., Zhao, J., Liang, X., & Wang, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00456 · Cited by 10
Venoms As an Adjunctive Therapy for Parkinson’s Disease: Where are We Now and Where are We going?
Gazerani, P. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0119 · Cited by 10
Beneficial Influence of Exendin-4 on Specific Organs and Mechanisms Favourable for the Elderly with Concomitant Obstructive Lung Diseases
Figat, M., Kardas, G., Kuna, P., & Panek, M. (2022) · Brain Sciences · doi:10.3390/brainsci12081090 · Cited by 10
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Salvadè, M., Luca, M. D., & Gardoni, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117862 · Cited by 12
The Role of β-Adrenergic Blockers in Parkinson’s Disease
Lương, K. V. Q., & Nguyễn, L. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513488919 · Cited by 9
Exendin-4 as a Versatile Therapeutic Agent for the Amelioration of Diabetic Changes
Rajabi, H., Ahmadi, M., Aslani, S., Saberianpour, S., & Rahbarghazi‬, R. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.025 · Cited by 9
L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease
Elabi, O. F., Davies, J. S., & Lane, E. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212346 · Cited by 9
Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson’s Disease Using In Vitro Models
Shtilbans, A., Esneault, E., Simon, F., Mazzulli, J. R., Quiriconi, D. J., Rom, D., Reintsch, W., Krahn, A. I., & Durcan, T. M. (2025) · Antioxidants · doi:10.3390/antiox14040396 · Cited by 8
Alterations of thyroidal status in brain regions and hypothalamo-pituitary-blood-thyroid-axis associated with dopaminergic depletion in substantia nigra and ROS formation in different brain regions after MPTP treatment in adult male mice
Sinha, P., Chakrabarti, N., Ghosh, N., Mitra, S., Dalui, S., & Bhattacharyya, A. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.12.013 · Cited by 8
4-Hydroxy TEMPO Attenuates Dichlorvos Induced Microglial Activation and Apoptosis
Sunkaria, A., Sharma, D. R., Wani, W. Y., & Gill, K. D. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400206w · Cited by 8
A Research Update on Exendin-4 as a Novel Molecule Against Parkinson’s Disease
Singh, N. K., Singh, A., Varshney, M., & Agrawal, R. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230529093314 · Cited by 9
Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?
Bagnoli, E., & FitzGerald, U. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14115 · Cited by 8
Glucagon‐like Peptides (GLP‐1) Perspectives in Synucleinopathies Treatment
Foltynie, T., & Athauda, D. S. (2018) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12611 · Cited by 7
Exendin-4 inhibits endothelial protein C receptor shedding in vitro and in vivo
Ku, S., Han, M. S., Park, E. J., Na, D. H., & Bae, J. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.04.005 · Cited by 7
Parkinson’s disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics
Foroozanmehr, B., Hemmati, M. A., Yaribeygi, H., Karav, S., Jamialahmadi, T., & Sahebkar, A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149738 · Cited by 6
Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease
Lee, S. M. L., Yin, L., Xiao, N., Rhee, T. G., Lo, H. K. Y., Wong, S., Fox, S. H., Teopiz, K. M., Lam, B. Y., Zheng, Y. J., et al. (2025) · CNS Spectrums · doi:10.1017/s109285292510031x · Cited by 6
Dulaglutide Alleviates Alzheimer's Disease by Regulating Microglial Polarization and Neurogenic Activity
Wang, Y., & Han, B. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220726163514 · Cited by 6
Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits Aβ25-35-induced apoptosis in PC12 cells by suppressing the expression of endoplasmic reticulum stress-related proteins.
Zhang, J., Wu, J., Zeng, W., Zhao, Y., & Zu, H. (2015) · PubMed Central · Cited by 6
GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 7
The Dipeptidyl Peptidase-4 Inhibitor Saxagliptin as a Candidate Treatment for Disorders of Consciousness: A Deep Learning and Retrospective Clinical Analysis
Toker, D., Chiang, J. N., Vespa, P. M., Schnakers, C., & Monti, M. M. (2025) · Neurocritical Care · doi:10.1007/s12028-025-02217-0 · Cited by 6
Exendin-4 protects the dopaminergic neurons by attenuating inflammatory responses of microglial cells via activation of AMPK
Rimal, N., Khanal, S., Bohara, G., & Choi, D. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110643 · Cited by 5
New fraternine analogues: Evaluation of the antiparkinsonian effect in the model of Parkinson's disease
Mayer, A. B., Amaral, H. D. O., de Oliveira, D. G. R., Campos, G. A. A., Ribeiro, P. G., Rego, S., de Souza, A. C. B., de Castro, R. J. A., Bocca, A. L., & Mortari, M. R. (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102390 · Cited by 4
Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer’s Disease
Crook, H., & Edison, P. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240730 · Cited by 5
Gut Hormones Restrict Neurodegeneration in Parkinson’s Disease
Bayliss, J. A., Stark, R., Reichenbach, A., & Zane, B. (2011) · InTech eBooks · doi:10.5772/28028 · Cited by 6
Microglia sensing of peripheral signals that bridge the brain and body
Young, C. E., & Samuel, M. A. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00905-1 · Cited by 6
Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis
Nogueira, L., Mazetto, R. A. S. V., Defante, M. L. R., Antunes, V., Gonçalves, O. R., Corso, A. M. S., Coletta, M. V. D., Boone, D. L., Filho, W. S. M., Borges, V., et al. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1806824 · Cited by 3
Targeting with toxins: an overview of venom peptides in drug delivery
Mazurs, A., Mauriņa, B., Bandere, D., & Logviss, K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126193 · Cited by 6
M14 substitutions in exanatide modulate alpha‐synuclein aggregation
Panuganti, V., Manchanda, K., Bharatam, P. V., & Roy, I. (2025) · FEBS Journal · doi:10.1111/febs.70321 · Cited by 3
The role of amphipathic and cationic helical peptides in Parkinson's disease
Pintado‐Grima, C., & Ventura, S. (2024) · Protein Science · doi:10.1002/pro.70020 · Cited by 3
Inhibitory effect of exendin-4 on secretory group IIA phospholipase A2
Lee, W., Kwak, S., Lee, H., Na, D. H., Lee, Y. M., & Bae, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.165 · Cited by 3
The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease
Teil, M., & Huot, P. (2026) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2025.103164 · Cited by 2
Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum — Mechanisms, evidence, and future directions
Dahshan, A., Khalil, M. I. M., El-Jaafary, S. I., & Yamani, A. (2026) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2026.100461 · Cited by 2
AETIQ: A Novel Synthetic Compound with Anti-inflammatory Properties in Activated Microglia
Son, H. J., Shin, N., Shin, E. J., Yoon, D., Seo, J. W., Lee, C.-S., & Hwang, O. (2014) · Inflammation · doi:10.1007/s10753-013-9795-8 · Cited by 2
Alzheimer’s Disease Drugs in Clinical Trials
Sheerin, M., & Adejare, A. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00013-1 · Cited by 2
Lactobacillus acidophilus exerts neuroprotective effects in MPTP mice: potential links to the gut microbiota and GLP-1
Yang, L., Guo, T., Wei, Y., Zhang, Z., Sun, Y., Yan, N., Ding, S., Jiang, L., & Liu, H. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115229 · Cited by 1
Combination Disease‐Modifying Therapy for Neurodegenerative Diseases Using Repurposed Drugs
Shtilbans, A., & Lang, A. E. (2026) · Annals of Neurology · doi:10.1002/ana.78190 · Cited by 1
DEMONSTRATION OF PRECISE RELATIONSHIPS AND LINKS BETWEEN TYPE 2 DIABETES MELLITUS, INSULIN RESISTANCE AND PARKINSON’S DISEASE
Rehman, H. U., Kaleemullah, & Tareen, A. M. (2020) · International Journal of Research -GRANTHAALAYAH · doi:10.29121/granthaalayah.v7.i12.2019.320 · Cited by 1
The Past, Present, and Future of Parkinson's Disease Treatment
Park, S. (2020) · Open Science Journal · doi:10.23954/osj.v5i4.2622 · Cited by 1
Self-citation
Applications in medicine: mental health
Janssens, Y., Wynendaele, E., Audenaert, K., & Spiegeleer, B. M. J. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821389-6.00020-0 · Cited by 1
Epigenetics and regenerative medicine
Ehnes, D. D., Levy, S., & Ruohola‐Baker, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00019-0 · Cited by 1
Pleiotropic Effects of an Incretin Hormone
Oh, S. (2013) · Journal of Korean Diabetes · doi:10.4093/jkd.2013.14.3.120
Exenatide as a novel treatment for Parkinson's Disease
Avilés-Olmos, I. (2013) · UCL Discovery (University College London)
Exendin-4 increases extracellular superoxide dismutase expression in cultured astrocytes
Takano, K., komada, Y., kawabe, K., Moriyama, M., & Nakamura, Y. (2017) · Global Drugs and Therapeutics · doi:10.15761/gdt.1000s1001
Hormones of energy homeostasis : linking weight loss and cognition in Parkinson's disease?
Johnston, F. (2018)
Avaliação neuroprotetora do peptídeo Occidentalina-1202 em modelo murino da doença de Parkinson
Amaral, H. D. O. (2018) · doi:10.26512/2018.tcc.20914
Faculty Opinions recommendation of Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Poewe, W. H., & Mahlknecht, P. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727879031.793537429
Glucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
Lactobacillus Acidophilus Ameliorated Motor Deficits and Neuroinflammation in a Mouse Model of Parkinson's Disease by Regulating Gut Microbiota and GLP-1Preprint
Yang, L., Guo, T., Wei, Y., Zhang, Z., Sun, Y., Yan, N., Ding, S., Jiang, L., & Liu, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5082895
Bridging the gap: Unveiling the gut's influence on Parkinson's disease through probiotic interventions
Nápoles-Medina, A. Y., Aguilar-Uscanga, B. R., Nápoles-Medina, B. G., Brand-Rubalcava, P. A., Tejeda-Martínez, A. R., & Flores-Soto, M. E. (2025) · Neurology Perspectives · doi:10.1016/j.neurop.2025.100206
GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer’s and Parkinson’s disease
Hölscher, C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1906426
Stroke-induced stem cells proliferation in normal versus diabetic mice and pharmacological regulation
Fadhel, Z. (2015)

Authors: Kim, S., Moon, M., & Park, S.
Affiliations: Kyung Hee University (KR)
Corresponding author: Park, Seungjoon
ORCID: Kim, Sehee
Moon, Minho
Venue: Journal of Endocrinology
Publisher: Bioscientifica
Published: 2009-06-29
Volume: 202
Issue: 3
Pages: 431-439
ISSN: 0022-0795 (ISSN-L)
1479-6805
DOI: 10.1677/joe-09-0132
OpenAlex: W2164948885
Cited by: 263
References: 55
Citations by year: 2026: 6 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 21 · 2021: 22 · 2020: 12 · 2019: 18 · 2018: 20 · 2017: 17 · 2016: 22 · 2015: 19 · 2014: 17 · 2013: 17 · 2012: 15
FWCI: 6.18
Type: journal article
Language: en
Open access: closed
Locations: Journal of Endocrinology (publishedVersion)
PubMed (publishedVersion)
Funders: Korea Science and Engineering Foundation
Ministry of Education and Human Resources Development
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: exendin-4, Parkinson's disease, dopaminergic neurons, microglial activation, matrix metalloproteinase-3, MPTP-induced neurotoxicity, substantia nigra pars compacta, neuroprotection, GLP-1 receptor, neuroinflammation, TNF-α, IL-1β, nigrostriatal degeneration
MeSH terms: Exenatide, Animals, Corpus Striatum, Disease Models, Animal, Dopamine, Gliosis, Hypoglycemic Agents, Male, Mice, Inbred C57BL, Peptides, Substantia Nigra, Venoms, Gene Expression Regulation, Enzymologic, Microglia, Neuroprotective Agents, Inflammation Mediators, Matrix Metalloproteinase 3, Parkinsonian Disorders, Mice, Matrix Metalloproteinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks